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Resistance to chemotherapy in cancer patients has been correlated to the overexpression of the ATPbinding cassette (ABC) drug transporters including P-glycoprotein (P-gp) that actively efflux chemotherapeutic drugs from cancer cells. We examined the mutidrug resistance reversing property of stemofoline
derivatives in drug-resistance human cervical carcinoma (KB-V1) and human leukemic (K562/Adr) cell lines
that overexpress P-gp. Didehydrostemofoline and eleven of its derivatives were synthesized and the cytotoxicity and their effect on doxorubicin, vinblastine and paclitaxel sensitivity in drug resistant (KB-V1 and K562/
Adr) and drug sensitive (KB-3-1 and K562) cell lines by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay were determined. We found that three out of the twelve stemofoline derivatives
including OH-A1, NH-B6 and NH-D6 showed commitment efficiency to increase sensitivity to doxorubicin,
vinblastine and paclitaxel in KB-V1 cells and increase sensitivity to doxorubicin, and paclitaxel in K562/Adr
cells whereas the effects have not been seen in their parental sensitive cancer cell lines (KB-3-1 and K562).
These results indicate that stemofoline derivatives reversed P-gp-mediated multidrug resistance in vitro, and
thus could be developed as effective chemosensitizers to treat multidrug-resistant cancers. The molecular
mechanism of modulation of P-gp would be further determined.
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The development and strategic use of anticancer drugs has
become one of the most important ways of controlling malignant disease. However, the emergence of drug resistance has
made many of the currently available chemotherapeutic agents
ineffective. Drug resistance is a major impediment to the
treatment of cancer patients receiving single or multiple drugs.
Efforts to reverse the drug resistance of tumor cells have
been largely unsuccessful.1) In recent years, considerable research has been directed toward understanding the underlying
mechanisms that confer drug resistance. Many studies using
tumor cell lines as model systems have demonstrated that exposure of cells to one drug often results in cross-resistance to
many other structurally, chemically, and functionally distinct
agents. This phenomenon is broadly known as the multidrug
resistant (MDR) phenotype.2–5) The mechanism of MDR now
has been shown that some of the ATP-binding cassette (ABC)
transporter proteins especially ABCB1, or as it is more commonly referred to in the literature as P-glycoprotein (P-gp),
which is normally expressed in tumors derived from epithelial
tissues, including cancers of the kidney, liver, colon and brain,
has been associated with intrinsic drug resistance of these
cancers.6) Some other tumors (for example breast, ovarian and
small cell lung cancers) exhibit generally low levels of P-gp
expression at diagnosis. However, the P-gp expression can be
induced during the course of treatment, causing the cancer to
become resistant to anticancer drugs.6) P-gp has been proven
to be responsible for resistance to a variety of structurally and
functionally unrelated antitumor drugs, including, vinblastine,
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vincristine, doxorubicin, daunorubicin, etoposide, teniposide
and paclitaxel.4,7,8) At present, due in part to the disappointing
results associated with the many side effects of P-gp modulators that have been used in clinical trials, current research
efforts are directed towards the identification of novel compounds with attention to dietary natural products or dietary
herbs such as curcumin,9–11) stemofoline12) and kuguacin J.13)
The advantage is that these dietary herbs might exhibit little
or virtually no side effect and further, do not increase the patient’s medication burden. The investigation of natural product
compounds to modulate the function of this transporter will
be useful for treating cancer patients in combination with the
conventional chemotherapy.
Stemona (non-tai-yak) has been used as an ingredient in
Thai folk medicines. Recent study demonstrated that Stemona collinsiae root extract exerted anticancer effect against
cell proliferation in cancer cell lines, including the human
hepatocellular carcinomas cell line (HepG2) and the human
breast cancer cell line (MCF-7)14) and antiviral property in
human herpes virus.15) In our previous study, Stemona alkaloids including stemofoline from Stemona burkillii, stemocurtisine and oxystemocurrine from Stemona aphylla have
been isolated and evaluated for synergistic growth inhibitory
effect with cancer chemotherapeutic agents.16) We found that
stemofoline had the ability to reverse the MDR phenotype,
increased the intracellular accumulation of P-gp fluorescent
substrates, decreased the [3H]-vinblastine efflux in multidrugresistant human cervical carcinoma KB-V1 cells and increased
their sensitivity to vinblastine, paclitaxel and doxorubicin.12,16)
In this study, twelve stemofoline derivatives were prepared
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Fig. 1. Structure of Stemofoline (a) and Its Derivatives (b)

from didehydrostemofoline according to the literature17,18) and
investigated for their MDR phenotype reversing properties in
human MDR cell lines, KB-V1 cells and leukemic K562/Adr
cells. Our results revealed that three of the 12 stemofoline
derivatives including, OH-A1, NH-B6 and NH-D6 increased
the intracellular accumulation and cytotoxicity of chemotherapeutic drugs in drug-resistant human cervical carcinoma and
leukemic cell lines in vitro.

Experimental

Chemicals Doxorubicin (Dox), verapamil (Ver), vinblastine (Vin), paclitaxel (PTX), 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) were obtained from
Sigma Chemical Company (St. Louis, MO, U.S.A.). Dulbecco’s modified Eagle’s medium (DMEM) and Roswell Park
Memorial Institute 1640 medium (RPMI1640) were purchased
from Gibco BRL (Grand Island, NY, U.S.A.).
The twelve stemofoline derivatives comprised didehydrostemofoline (OH-A1), five alcohol derivatives (OH-C3, OH-C4,
OH-C5, OH-E3 and OH-E4) and six of amine derivatives
(NH-A3, NH-A7, NH-B6, NH-C1, NH-C3 and NH-D6). These
derivatives were prepared from didehydrostemofoline according to the literature.17,18)
Cells and Cell Culture A MDR cervical carcinoma cell
line (KB-V1) and a drug-sensitive cervical carcinoma cell line
(KB-3-1) were generous gifts from Dr. Michael M. Gottesman
(National Cancer Institute, Bethesda, MD, U.S.A.). Both cell
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lines were cultured in DMEM with 4.5 g of glucose/L plus
10% fetal bovine serum (FBS), 5 m m l-glutamine, 50 IU/mL
penicillin and 50 mg/mL streptomycin; 1 µm of Vin was added
only to the KB-V1 culture medium.
A MDR leukemic cell line (K562/Adr) was purchased from
RIKEN Cell Bank (Tsukuba, Ibaraki, Japan). A drug-sensitive
leukemic cell line (K562) was purchased from The American
type Culture Collection (ATCC, Manassas, VA, U.S.A.). Both
cell lines were cultured in RPMI1640 with 10% fetal bovine
serum (FBS), 5 m m l-glutamine, 50 IU/mL penicillin and 50 g/
mL streptomycin; 700 n m of Dox was added only to the K562/
Adr culture medium.
These cell lines were maintained in a humidified incubator
with an atmosphere comprising 95% air and 5% CO2 at 37°C.
When the cells reached 70–80% confluence, they were harvested and plated either for subsequent passages or for drug
treatments.
Cytotoxicity Assay KB-V1 and KB-3-1 cells were plated
at 1.0×103 cells per well in 96-well plates. Twenty four hours
after plating (these cell lines are adherent cell that require
time period for culture-plate surface adhesion), the cells were
incubated with stemofoline derivatives (2.5, 5, 10, 20, 40 µm)
for 48 h at 37°C.
K562 and K562/Adr cells were plated at 9.0×103 cells per
well in 96-well plates. Two hours after plating (these cell lines
are non-adherent cell which not require time period for the
adhesion), increasing concentrations of stemofoline derivatives
(5, 10, 20, 40, 50 µm) were added and the cells were then further incubated for 48 h at 37°C.
Overall cell number/viability was assessed by MTT assay.19)
In each experiment, determinations were carried out in triplicate.
Chemosensitivity Testing For measurement of Dox, Vin
and PTX cytotoxicity, KB-V1 and KB-3-1 cells were plated
at 1.0×103 cells per well in 96-well plates. After 24 h, stemofoline derivatives and various concentrations of Dox or
Vin or PTX were added. The cells were incubated for 48 h at
37°C, and then cell growth was assessed by means of an MTT
colorimetric assay.20) In each experiment, determinations were
carried out in triplicate. Relative resistance was calculated as
the ratio of the IC50 value of the KB-V1 cells to the IC50 value
of the KB-3-1 cells.
For measurement of Dox and PTX cytotoxicity, K562/Adr
and K562 cells were plated at 9.0×103 cells per well in 96-well
plates. After 2 h, stemofoline derivatives and various concentrations of Dox or PTX were added. The cells were incubated
for 48 h at 37°C, and then cell growth was assessed by means
of an MTT colorimetric assay.20) In each experiment, determinations were carried out in triplicate. Relative resistance was
calculated as the ratio of the IC50 value of the K562/Adr cells
to the IC50 value of the K562 cells.
Statistical Analysis The results are presented as means±
S.D. from triplicate samples of three independent experiments.
Differences between the means were analyzed by one-way
ANOVA. Statistical significance was considered when p<0.05,
or p<0.01, or p<0.001. All statistical analyses were performed
using Prism 5.0 software.

Results

Effects of Stemofoline Derivatives on the Cytotoxicity of
KB-V1, KB-3-1, K562/Adr and K562 Cells Cytotoxicity
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Table 1. Modulation of Resistance to Dox in KB Cells by Stemofoline
Derivatives
IC50a)
Doxorubicin treatment
KB-3-1
KB-V1
Stemofoline derivative
KB-V1+5 µm of OH-A1
KB-V1+5 µm of OH-C3
KB-V1+5 µm of OH-C4
KB-V1+5 µm of OH-C5
KB-V1+5 µm of OH-E3
KB-V1+5 µm of OH-E4
KB-V1+5 µm of NH-A3
KB-V1+5 µm of NH-A7
KB-V1+5 µm of NH-B6
KB-V1+5 µm of NH-C1
KB-V1+5 µm of NH-C3
KB-V1+5 µm of NH-D6
KB-V1+5 µm of stemofoline

0.23±0.03 nm
3.40±0.36 µm
0.72±0.26 µm***
2.63±1.88 µm
2.80±0.20 µm
3.43±0.12 µm
3.07±0.46 µm
3.47±0.50 µm
1.58±0.33 µm**
4.27±0.93 µm
0.78±0.19 µm***
3.93±0.31 µm
3.97±0.12 µm
1.48±0.20 µm***
1.33±0.58 µm***

Table 2. Modulation of Resistance to PTX in KB Cells by Stemofoline
Derivatives

Relative resistanceb)
1.00±0.00
17±0.00
4±1.30***
13±5.90
14±1.00
17±0.60
15±2.30
17±2.50
8±1.70**
21±4.60
4±0.90***
20±1.50
20±0.60
7±1.00***
7±2.90 ***

a) Determined by the MTT assay, and the values are means±S.D. of three independent experiments. b) IC50 of KB-V1/IC50 of KB-3-1. Each point represents the
mean (±S.D.) of three independent experiments performed in triplicate. ** p<0.01
and *** p<0.001, vs. control treated without stemofoline derivatives.

assays showed that the stemofoline derivatives (treatment with
0–40 µm for 48 h) were not cytotoxic to KB-V1, KB-3-1, K562/
adr and K562 cells (data not shown). The compounds which
were applied in all subsequent experiments are at the final
concentration of 5 µm (>90% cell survival).
Effect of Stemofoline Derivatives on Cytotoxicity of Dox,
PTX and Vin in KB-3-1 and KB-V1 Cells To examine
the MDR reversing property of stemofoline derivatives on
Dox, PTX and Vin cytotoxicity, the growth inhibition of
cells was investigated in response to increasing concentrations of Dox, PTX or Vin with or without each stemofoline
derivative. The results showed that 5 µm of OH-A1, NH-B6
and NH-D6 dramatically increased sensitivity of KB-V1
cells to Dox, PTX and Vin, 5.0- (p<0.001), 4.4- (p<0.001)
and 2.3-fold (p<0.001), respectively for Dox, 3.0- (p<0.001),
3.2- (p<0.001) and 1.5-fold, respectively for PTX, and 5.8(p<0.001), 4.3- (p<0.001) and 3.6-fold (p<0.001), respectively
for Vin. Besides, NH-A3 treatment also significantly increased
sensitivity of KB-V1 cells to Dox (2.1-fold, p<0.01) and PTX
(2.1-fold, p<0.01). While similar treatment of KB-3-1 cells
provided no modulating effect (Tables 1–3, Figs. 2a–f).
Effect of Stemofoline Derivatives on Cytotoxicity of Dox
and PTX in K562 and K562/Adr Cells 
To examine the
MDR reversing property of stemofoline derivatives on Dox,
and PTX cytotoxicity, the growth inhibition of cells was investigated in response to increasing concentrations of Dox or
PTX with or without each stemofoline derivatives. The results
showed that 5 µm of OH-A1, NH-B6 and NH-D6 significantly
(p<0.001) increased sensitivity of K562/Adr cells to Dox and
PTX, 3.7-, 7.6- and 2.3-fold, respectively for Dox, 5.6-, 19.5and 3.9-fold, respectively for PTX while similar treatment of
K562 cells provided no modulating effect (Tables 4, 5, Figs.
3a–d).

Paclitaxel treatment
KB-3-1
KB-V1
Stemofoline derivative
KB-V1+5 µm of OH-A1
KB-V1+5 µm of OH-C3
KB-V1+5 µm of OH-C4
KB-V1+5 µm of OH-C5
KB-V1+5 µm of OH-E3
KB-V1+5 µm of OH-E4
KB-V1+5 µm of NH-A3
KB-V1+5 µm of NH-A7
KB-V1+5 µm of NH-B6
KB-V1+5 µm of NH-C1
KB-V1+5 µm of NH-C3
KB-V1+5 µm of NH-D6
KB-V1+5 µm of stemofoline

IC50a)

Relative resistanceb)

1.52±0.08 nm
7.00±0.10 µm

1.00±0.00
4773±227

3.50±0.87 µm***
9.75±2.05 µm
10.33±1.89 µm
9.17±1.04 µm
10.67±2.02 µm
11.17±2.25 µm
5.77±1.50 µm**
7.17±1.15 µm
3.27±1.57 µm***
9.83±1.76 µm
12.00±0.87 µm
6.80±1.74 µm*
1.43±0.45 µm***

1591±394***
4432±930
4697±860
4167±473
4848±919
5076±1,025
2621±684**
3254±525
1485±713***
4470±798
5455±394
3091±793
652±205***

a) Determined by the MTT assay, and the values are means±S.D. of three independent experiments. b) IC50 of KB-V1/IC50 of KB-3-1. Each point represents the
mean (±S.D.) of three independent experiments performed in triplicate. ** p<0.01
and *** p<0.001, vs. control treated without stemofoline derivatives.

Table 3. Modulation of Resistance to Vin in KB Cells by Stemofoline
Derivatives
IC50a)
Vinblastine treatment
KB-3-1
KB-V1
Stemofoline derivative
KB-V1+5 µm of OH-A1
KB-V1+5 µm of OH-C3
KB-V1+5 µm of OH-C4
KB-V1+5 µm of OH-C5
KB-V1+5 µm of OH-E3
KB-V1+5 µm of OH-E4
KB-V1+5 µm of NH-A3
KB-V1+5 µm of NH-A7
KB-V1+5 µm of NH-B6
KB-V1+5 µm of NH-C1
KB-V1+5 µm of NH-C3
KB-V1+5 µm of NH-D6
KB-V1+5 µm of stemofoline

Relative resistanceb)

0.61±0.01 µm
0.60±0.05 µm

1.00±0.00
984±0.00

0.11±0.04 µm ***
0.71±0.05 µm
0.73±0.05 µm
0.68±0.09 µm
0.67±0.08 µm
0.74±0.09 µm
0.61±0.14 µm
0.65±0.08 µm
0.15±0.04 µm ***
0.61±0.13 µm
0.74±0.05 µm
0.18±0.05 µm ***
0.09±0.01 µm***

187±71.50***
1164±71.10
1202±78.60
1121±151.40
1093±123.10
1212±131.30
993±220.50
1070±108.50
240±64.80***
1008±235.40
1214±106.30
290±81.80***
142±21.10***

a) Determined by the MTT assay, and the values are means±S.D. of three independent experiments. b) IC50 of KB-V1/IC50 of KB-3-1. Each point represents the
mean (±S.D.) of three independent experiments performed in triplicate. *** p<0.001,
vs. control treated without stemofoline derivatives.

Discussion

Resistance to chemotherapy is a major problem in the management of cancer patients and is caused by various molecular
mechanisms. One of these mechanisms is the overexpression of MDR1/P-glycoprotein, which is the major cause of
multidrug-resistance (MDR) of human cancers. Potent MDR
modulators are being investigated in clinical trials. Verapamil,
a calcium channel blocker, and cyclosporin A, an immunosuppressive agent are effective P-gp inhibitors in vitro, but they
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Fig. 2. The Effect of Stemofoline Derivatives (OH-A1, NH-B6 and NH-D6) on Dox, PTX and Vin Cytotoxicity in KB-V1 ((a), (c), (e)) and KB-3-1
((b), (d), (f)) Cell Lines
Cells were incubated in the presence or absence of stemofoline derivatives (OH-A1, NH-B6 and NH-D6) in combination with Dox or PTX or Vin. The number of viable
cells was determined by an MTT assay. The Y-axis shows the percent of cell survival, and the X-axis shows varying concentrations of stemofoline derivatives. Each point
represents the mean of three independent experiments performed in triplicate.

have limited clinical use. Many current studies are focused
on the use of dietary herbs as alternatives due to the fact that
these have been used for centuries without producing any
harmful side effects.10,11,21–23)
The present study has determined the MDR reversing property of stemofoline derivatives on the cytotoxicity of Dox,
PTX or Vin in KB-V1 and KB-3-1 cell lines. It was found
that OH-A1, NH-B6 and NH-D6 markedly increased the
sensitivity of KB-V1 cells to Dox, PTX, and Vin, but did not
have this effect on KB-3-1 cells (Tables 1–3, Figs. 2a–f). The

similar study in K562/Adr and K562 cell lines also showed
that OH-A1, NH-B6 and NH-D6 significantly increased the
sensitivity of K562/Adr cells to Dox, and PTX, but did not
have the effect on K562 cells (Tables 4, 5, Figs. 3a–d). Our
previous report demonstrated that Stemona extract did not
influence MDR-mediated multidrug resistance protein 1
(MRP-1) but P-gp,24) while PTX is a P-gp specific substrate
that differ from Dox and Vin which are the substrates of the
MRP-1 as well.25,26) These might be the reason why the reversing property of stemofoline and its derivatives including
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Table 4. Modulation of Resistance to Dox in K562 Cells by Stemofoline
Derivatives
IC50a)
Doxorubicin treatment
K562
K562/Adr
Stemofoline derivative
K562/Adr+5 µm of OH-A1
K562/Adr+5 µm of NH-B6
K562/Adr+5 µm of NH-D6
K562/Adr+5 µm of stemofoline

453.33±5.77 nm
17.33±1.15 µm
4.70±0.26 µm***
2.27±0.49 µm***
7.57±0.40 µm***
4.47±0.55 µm***

Table 5. Modulation of Resistance to PTX in K562 Cells by Stemofoline
Derivatives

Relative resistanceb)
1.00±0.00
38.23±2.35
10.37±0.64***
5.01±1.14***
16.69±0.95***
9.85±1.22***

a) Determined by the MTT assay, and the values are means±S.D. of three independent experiments. b) IC50 of K562/Adr/IC50 of K562. Each point represents the
mean (±S.D.) of three independent experiments performed in triplicate. *** p<0.001,
vs. control treated without stemofoline derivatives.

IC50a)
Paclitaxel treatment
K562
K562/Adr
Stemofoline derivative
K562/Adr+5 µm of OH-A1
K562/Adr+5 µm of NH-B6
K562/Adr+5 µm of NH-D6
K562/Adr+5 µm of stemofoline

8.17±0.76 nm
0.78±0.03 µm
0.14±0.01 µm***
0.04±0.01 µm***
0.20±0.02 µm***
0.10±0.02 µm***

Relative resistanceb)
1.00±0.00
96.34±7.44
16.90±2.84***
5.30±0.28***
25.17±4.48***
12.30±2.34***

a) Determined by the MTT assay, and the values are means±S.D. of three independent experiments. b) IC50 of K562/Adr/IC50 of K562. Each point represents the
mean (±S.D.) of three independent experiments performed in triplicate. *** p<0.001,
vs. control treated without stemofoline derivatives.

Fig. 3. The Effect of Stemofoline Derivatives (OH-A1, NH-B6 and NH-D6) on Dox and PTX Cytotoxicity in K562/Adr ((a), (c)) and K562 ((b), (d))
Cell Lines
Cells were incubated in the presence or absence of stemofoline derivatives (OH-A1, NH-B6 and NH-D6) in combination with Dox or PTX. The number of viable cells
was determined by an MTT assay. The Y-axis shows the percent of cell survival, and the X-axis shows varying concentrations of stemofoline derivatives. Each point represents the mean of three independent experiments performed in triplicate.

OH-A1, NH-B6 and NH-D6 in PTX-treated cells was greater
than in Dox-, and Vin-treated cells.
Stemofoline and its derivatives have a common caged structure but different side chain structures. While the number of
compounds studied is limited making any structure–activity
relationship discussions only tenuous, it is clear that none of
the alcohol derivatives tested, specifically compounds OH-C3,
OH-C4, OH-C5, OH-E3 and OH-E5, were active. The presence of hydroxyl group (–OH) may reduce the bioactivity. In
contrast the primary benzylamino derivative NH-B6 and the

carbamate derivative NH-D6 were active modulators along
with didehydrostemofoline (OH-A1), the alkene derivative of
stemofoline. In some cases (Tables 1–3) these three derivatives had similar or lower activities than stemofoline. In some
cases, especially in the treatment of K562/Adr, NH-B6 showed
the most efficacy (Tables 4, 5), while stemofoline were more
effective than OH-A1 (Tables 4, 5). The lower activity of
OH-A1 compared to stemofoline may be because of the less
flexible side chain of OH-A1. The presence of 2S-phenylethyl
group in NH-B6 may be significant for enhancement of its
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MDR reversing property. In one study, the morpholine derivative NH-A3 (Tables 1, 2) was nearly as effective as stemofoline itself. This latter compound was not very effective in the
other studies (Table 3).
Our previous study showed that P-gp function was inhibited, but not its expression in KB-V1 when treating the cells
with stemofoline.12) The present study provided the reversal of
P-gp-mediated MDR by stemofoline derivatives in P-gp overexpressing cancer cell lines, KB-V1 and K562/Adr. The mechanism of MDR reversal by stemofoline derivatives might be
via the inhibition of expression and/or function of P-gp. Thus,
the modulation of stemofoline derivatives, especially NH-B6,
on P-gp function and expression would be further determined
to observe their molecular mechanisms.

Conclusion

In conclusion, this study is the first to demonstrate the
structure–activity relationships of stemofoline derivatives
on MDR reversing property, which could be introduced as
candidate molecules for treating cancers exhibiting P-gp-mediated MDR. Animal experiments should be further studied
to determine if these compounds have potential as effective
chemosensitizers to be used in combination with conventional
chemotherapy.
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